Navigation Links
Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Women's Cancer
Date:3/4/2008

SOUTH SAN FRANCISCO, Calif., March 4 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, will present data at the upcoming 39th Annual Meeting on Women's Cancer hosted by the Society of Gynecologic Oncologists (SGO). This year's conference will be held March 9-12, 2008 at the Tampa Convention Center in Tampa, Fla.

Interim data from Sunesis' ongoing Phase 2 clinical trial of SNS-595 in platinum-resistant ovarian cancer will be featured in a poster, "A Phase 2 Trial of SNS-595 in Women with Platinum-Refractory Epithelial Ovarian Cancer"(Abstract # 290), beginning on Sunday, March 9, 2008. Presenting author William P. McGuire, M.D., Medical Director of the Harry and Jeanette Weinberg Cancer Institute at Franklin Square Hospital, and a lead investigator for the Phase 2 trial, will be available at the poster on Tuesday, March 11, 2008 between 2:00-3:00 p.m. to discuss the interim Phase 2 data. The poster will also be available following the conference on the Sunesis corporate website at http://www.sunesis.com.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling. The company's lead compound, SNS-595, is currently in a Phase 1b clinical trial in patients with acute leukemia and a Phase 2 clinical trial in patients with ovarian cancer. SNS-032, Sunesis' potent and selective inhibitor of cyclin-dependent kinases 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in chronic lymphocytic leukemia and multiple myeloma. SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and receptor tyrosine kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
2. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
5. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
6. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
7. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
8. SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results
9. NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
10. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
11. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016 /PRNewswire/ - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical ... immunotherapeutic products for the treatment of cancer, today ... Manufacturing Development Program with Cytovance Biologics ( ... oregovomab antibody product. Supported by recent positive interim ... in ovarian cancer patients, OncoQuest has engaged Cytovance ...
(Date:12/7/2016)... , Dec. 7, 2016  Biocom, the association for the ... statement below following passage of 21 st Century Cures ... November 30 by a 392-26 vote and in the Senate ... be attributed to Joe Panetta , president & CEO ... will give hope to millions of patients around the world. ...
(Date:12/7/2016)...  Genprex, Inc. a biopharmaceutical company focused on ... announced that it has retained ICR Healthcare, a ... and advisory firm, to develop and implement an ... investor relations, public relations and digital communications to ... Genprex and its lead candidate Oncoprex, which is ...
(Date:12/7/2016)... Regen BioPharma Inc. (OTCQB: RGBPP) In a recent ... team of scientists in Guangzhou, China ... of NR2F6 in patients with early cervical cancer correlates with ... cancer tissue as well as in the normal tissue surrounding ... study and the first that I am aware of that ...
Breaking Biology Technology:
(Date:12/7/2016)... 2016 According to a new market research report "Emotion ... Expression, Voice Recognition), Service, Application Area, End User, And Region - Global Forecast ... USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a ... Reading ... MarketsandMarkets Logo ...
(Date:12/6/2016)... Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... an offering of €500.0 million principal amount of its 1.414% ... of its 2.425% senior unsecured notes due 2026. ... on December 13, 2016, subject to the satisfaction of customary closing ... The Company intends to use ...
(Date:12/2/2016)... , December 1, 2016 ... type (Fingerprint, Voice), Future Technology (Iris Recognition System), ... Region - Global Forecast to 2021", published by ... 442.7 Million in 2016, and is projected to ... a CAGR of 14.06%.      (Logo: ...
Breaking Biology News(10 mins):